Boston Scientific reported $21.0B of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $21.0B (to Q2 2026). Net income: $3.67B, trailing twelve months to Q2 2026. Free cash flow: $3.63B, trailing twelve months to Q2 2026. Operating margin: 20%, trailing twelve months to Q2 2026.

BSXBoston Scientific

Healthcare

$42.75-56% 1Y

$42.75

$41.5852 weeks$104.98

BSX as reported

Boston Scientific reported $21.0B of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed.

$21.0B

Revenue, trailing twelve months · to Q2 2026 · +14% against the twelve months before

Net income: $3.67B
Net income · +47% year on year · trailing twelve months to Q2 2026
Free cash flow: $3.63B
Free cash flow · +4.0% year on year · trailing twelve months to Q2 2026
Operating margin: 20%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BSX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$21.0B	+14%	Q2 2026
Net income	$3.67B	+47%	Q2 2026
EPS	$2.47	+47%	Q2 2026
Gross margin	70%	n/a	Q2 2026
Operating margin	20%	n/a	Q2 2026
Net margin	17%	n/a	Q2 2026
ROE	13%	n/a	Q2 2026
ROA	7.3%	n/a	Q2 2026
ROIC	8.4%	n/a	Q2 2026
Free cash flow	$3.63B	+4.0%	Q2 2026
P/E	17.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.